{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    6,
    8,
    17,
    25,
    36,
    42,
    48,
    49,
    53
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_8",
        "affectedSection": "Schedule of Activities - Tumor Assessments",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Discontinuation of Blinded Independent Central Review (BICR) for disease progression assessment after final PFS analysis."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_8",
        "affectedSection": "Section 7.7 - Assessments",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Discontinuation of immune-related response criteria (irRECIST) data collection."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_8",
        "affectedSection": "Table 8 - Required Laboratory Tests",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Introduction of a specific laboratory test schedule for the period following the IA3 cut-off date (28-Apr-2020)."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_8",
        "affectedSection": "Section 1.3 - Summary of Benefit/Risk Assessment",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated safety monitoring requirements including MUGA/Echocardiogram and cardiac biomarkers (BNP, troponin, CK-MB) due to myocarditis cases."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_8",
        "reasonText": "Final PFS analyses specified in the protocol have been performed, allowing transition to investigator-assessed progression.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_8",
        "reasonText": "Occurrence of myocarditis cases in early phases of treatment necessitated enhanced cardiac monitoring guidelines.",
        "category": "Safety",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_8",
        "reasonText": "PACL dated 02 September 2019 mandated the cessation of irRECIST-defined antitumor activity collection.",
        "category": "Regulatory",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_8",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "Schedule of Activities",
        "beforeText": "Confirmed disease progression by BICR assessment",
        "afterText": "After review of images by BICR is stopped... permanent discontinuation of treatment will be performed as per investigator-assessed disease progression.",
        "summary": "Transitioned progression assessment from BICR to investigator assessment following final PFS analysis."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_8",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "7.7",
        "beforeText": "irRECIST-defined antitumor activity will be collected",
        "afterText": "irRECIST-defined antitumor activity will no longer be collected as per PACL dated 02 September 2019.",
        "summary": "Stopped collection of irRECIST data."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_8",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "Table 8",
        "afterText": "Required Laboratory Tests Post IA3 Cut Off Date (28-Apr-2020)",
        "summary": "Added a new table for laboratory requirements specific to the post-IA3 study phase."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_8",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "1.3",
        "afterText": "The study plans to monitor patients at regular intervals... including MUGA/Echocardiogram, ECG, BNP, troponin and CK-MB monitoring.",
        "summary": "Added intensive cardiac monitoring and myocarditis management instructions."
      }
    ],
    "summary": {
      "impactCount": 4,
      "reasonCount": 3,
      "changeCount": 4
    }
  }
}